Fayez Sarofim & Co’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.62M Buy
233,339
+200
+0.1% +$5.23K 0.01% 114
2026
Q1
$6.55M Sell
233,139
-3,148
-1% -$83.8K 0.02% 107
2025
Q4
$5.88M Sell
236,287
-10,410
-4% -$263K 0.01% 113
2025
Q3
$6.29M Hold
246,697
0.01% 119
2025
Q2
$5.98M Sell
246,697
-15,395
-6% -$359K 0.01% 123
2025
Q1
$6.64M Sell
262,092
-6,983
-3% -$183K 0.02% 115
2024
Q4
$7.14M Sell
269,075
-8,576
-3% -$233K 0.02% 111
2024
Q3
$8.04M Sell
277,651
-154,480
-36% -$4.51M 0.02% 106
2024
Q2
$12.1M Sell
432,131
-73,848
-15% -$2.03M 0.03% 92
2024
Q1
$14M Sell
505,979
-194,741
-28% -$5.4M 0.04% 87
2023
Q4
$19.3M Sell
700,720
-40,611
-5% -$1.23M 0.06% 80
2023
Q3
$24.6M Sell
741,331
-20,274
-3% -$717K 0.08% 77
2023
Q2
$27.9M Sell
761,605
-69,125
-8% -$2.69M 0.1% 75
2023
Q1
$33.9M Buy
830,730
+18,295
+2% +$790K 0.12% 75
2022
Q4
$41.6M Sell
812,435
-37,043
-4% -$1.78M 0.15% 71
2022
Q3
$37.2M Buy
849,478
+39,657
+5% +$1.93M 0.15% 70
2022
Q2
$42.5M Buy
809,821
+7,030
+0.9% +$358K 0.16% 71
2022
Q1
$41.6M Buy
802,791
+25,334
+3% +$1.31M 0.13% 75
2021
Q4
$45.9M Buy
777,457
+35,825
+5% +$1.77M 0.14% 76
2021
Q3
$31.9M Sell
741,632
-8,110
-1% -$359K 0.11% 81
2021
Q2
$29.4M Buy
749,742
+45,888
+7% +$1.78M 0.1% 81
2021
Q1
$25.5M Sell
703,854
-21,754
-3% -$772K 0.09% 78
2020
Q4
$26.7M Sell
725,608
-34,751
-5% -$1.27M 0.1% 75
2020
Q3
$26.5M Buy
760,359
+10,122
+1% +$355K 0.11% 73
2020
Q2
$23.3M Buy
750,237
+35,739
+5% +$1.21M 0.11% 74
2020
Q1
$22.1M Sell
714,498
-2,943
-0.4% -$100K 0.14% 70
2019
Q4
$26.7M Buy
717,441
+6,770
+1% +$241K 0.13% 74
2019
Q3
$24.2M Buy
710,671
+2,046
+0.3% +$74.4K 0.12% 73
2019
Q2
$29.1M Sell
708,625
-121,342
-15% -$4.82M 0.15% 69
2019
Q1
$33.4M Buy
829,967
+125,028
+18% +$5.01M 0.18% 66
2018
Q4
$29.2M Buy
704,939
+764
+0.1% +$31.7K 0.18% 68
2018
Q3
$29.4M Sell
704,175
-2,862
-0.4% -$110K 0.15% 69
2018
Q2
$24.3M Sell
707,037
-9,235
-1% -$316K 0.13% 70
2018
Q1
$24.1M Sell
716,272
-1,293
-0.2% -$44.5K 0.13% 71
2017
Q4
$24.7M Sell
717,565
-790
-0.1% -$26.9K 0.13% 70
2017
Q3
$24.3M Sell
718,355
-2,065
-0.3% -$66.4K 0.13% 73
2017
Q2
$23M Sell
720,420
-9,471
-1% -$299K 0.12% 77
2017
Q1
$23.7M Buy
729,891
+36,209
+5% +$1.14M 0.13% 76
2016
Q4
$21.4M Buy
693,682
+1,084
+0.2% +$33.1K 0.12% 77
2016
Q3
$22.3M Sell
692,598
-12,327
-2% -$412K 0.12% 75
2016
Q2
$23.5M Buy
704,925
+101,791
+17% +$3.25M 0.13% 76
2016
Q1
$17M Sell
603,134
-2,064
-0.3% -$59K 0.1% 83
2015
Q4
$18.5M Sell
605,198
-28,693
-5% -$903K 0.11% 81
2015
Q3
$18.9M Sell
633,891
-16,312
-3% -$523K 0.11% 83
2015
Q2
$20.7M Buy
650,203
+3,544
+0.5% +$116K 0.11% 76
2015
Q1
$21.3M Sell
646,659
-984
-0.2% -$31.3K 0.1% 75
2014
Q4
$19.1M Sell
647,643
-6,437
-1% -$185K 0.09% 75
2014
Q3
$18.4M Sell
654,080
-4,654
-0.7% -$131K 0.09% 75
2014
Q2
$18.6M Buy
658,734
+12,348
+2% +$352K 0.08% 75
2014
Q1
$19.7M Sell
646,386
-2,285
-0.4% -$68.1K 0.09% 75
2013
Q4
$18.9M Buy
+648,671
New +$18.9M 0.09% 75
2013
Q2
$19.8M Buy
+745,916
New +$20.6M 0.1% 71

Other funds holding PFE

Fayez Sarofim & Co's PFE Position: Q2 2026 in Review

Fayez Sarofim & Co increased its Pfizer (PFE) stake by 0.09% in Q2 2026, buying an estimated $5.23K and bringing the position to 233,339 shares worth $5.62M. The position accounts for 0.01% of the portfolio, ranked #114.

Fayez Sarofim & Co first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $45.9M in Q4 2021. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Fayez Sarofim & Co held 233,339 shares of Pfizer worth $5.62M as of Q2 2026.
  • Fayez Sarofim & Co bought 200 Pfizer shares in Q2 2026, an estimated $5.23K.
  • Pfizer made up 0.01% of Fayez Sarofim & Co's portfolio in Q2 2026, its #114 holding.
  • Fayez Sarofim & Co first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
  • Fayez Sarofim & Co's Pfizer position peaked at $45.9M in Q4 2021.
  • 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Fayez Sarofim & Co's 13F filing for Q2 2026, filed 17 Aug 2026.